Li et al. have reported that LAPTM4B could act on anthracycline trafficking by reducing drug entry to nucleus and decreasing drug-induced DNA damage, which leads to resistance and recurrence of BC [46]. This evidence concerns the gene LAPTM4B and breast cancer.